Pharmaceutical - Pharmaceutical, Pricing

Filter

Current filters:

PharmaceuticalPricing

Popular Filters

1 to 25 of 596 results

France negotiates lowest price in Europe for Gilead’s Sovaldi

France negotiates lowest price in Europe for Gilead’s Sovaldi

21-11-2014

The discount negotiated by the French government on hepatitis C drug Sovaldi (sofosbuvir), produced by…

FranceGilead SciencesNephrology and HepatologyPharmaceuticalPoliticsPricingRegulationSovaldi

Added benefit of Jardiance not proven, says IQWiG

19-11-2014

Following an examination as to whether Jardiance (empagliflozin) offers an added benefit over appropriate…

Boehringer IngelheimDiabetesEli LillyGermanyJardiancePharmaceuticalPricingRegulation

NICE seeks more information on Xolair to treat hives

19-11-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Swiss…

DermatologicalsNovartisPharmaceuticalPricingRegulationUKXolair

Ukrainian government to impose state control for drug prices in domestic market

Ukrainian government to impose state control for drug prices in domestic market

18-11-2014

The Ukraine government has officially imposed state control on the prices of drugs in the domestic market,…

PharmaceuticalPricingRegulationUkraineUkraine government

Internationally health economic evaluations are a fixed component of reimbursement decisions, says IQWiG

17-11-2014

Internationally health economic evaluations (HEEs) form a legally regulated fixed component in health-care…

GermanyGlobalPharmaceuticalPricingRegulation

Dynamic growth of pharmaceutical sales to hospitals in Poland

Dynamic growth of pharmaceutical sales to hospitals in Poland

13-11-2014

The year 2013 was better for the Polish pharmaceutical distribution market than 2012, when wholesale…

Markets & MarketingPharmaceuticalPMRPolandPricing

Report: Outcome-based data and value are vital for payers and HTAs

Report: Outcome-based data and value are vital for payers and HTAs

11-11-2014

Payers and regulators worldwide are moving towards value and outcome-based decision making for pricing…

BeroeGlobalPharmaceuticalPricingResearch

Scottish backing for Novartis’ Afinitor for kidney cancer patients

Scottish backing for Novartis’ Afinitor for kidney cancer patients

10-11-2014

The Scottish Medicines Consortium has issued a positive recommendation for Swiss pharma major Novartis’…

AfinitorClinical pharmacologyHealthHealth Medical PharmaNHSNovartisOncologyPharmaceuticalPricingRegulationUK

Global Pharma may suspend production of vital drugs for Russia

07-11-2014

Global pharmaceutical producers are considering suspending of production of vital drugs for the Russian…

FinancialPharmaceuticalPricingProductionRussia

Eisai “dismayed” by G-BA decision on Fycompa

06-11-2014

Japanese drug major Eisai has expressed “utmost disappointment” that the German Federal Joint Committee…

EisaiFycompaGermanyNeurologicalPharmaceuticalPricingRegulation

IQWIG confirms an additional benefit of Eisai's Halaven

IQWIG confirms an additional benefit of Eisai's Halaven

04-11-2014

Following a benefit:cost re-assessment, the German Institute for Quality and Efficiency in Health Care…

EisaiGermanyHalavenOncologyPharmaceuticalPricingRegulation

Added benefit of Takeda’s Entyvio is not proven, says IQWiG

Added benefit of Takeda’s Entyvio is not proven, says IQWiG

04-11-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products,…

EntyvioGastro-intestinalsGermanyPharmaceuticalPricingRegulationTakeda Pharmaceutical

Bristol-Myers reveals access plan for hep C drug daclatasvir

03-11-2014

US Pharma major Bristol-Myers Squibb has recently revealed a commercial strategy for sales of its new…

Anti-viralsBristol-Myers SquibbdaclatasvirDaklinzaMarkets & MarketingPharmaceuticalPricing

Spanish pharmaceutical market development

03-11-2014

Spanish pharma trade group Farmaindustria’s general assembly gathered in Madrid last week to hold an…

Esteve GroupManagementPharmaceuticalPricingRegulationSpain

New Zealand proposal for sole supply of Remicade in DHB hospitals

New Zealand proposal for sole supply of Remicade in DHB hospitals

31-10-2014

Following a Request for Tender for infliximab issued on September 2, 2014 (RFT), New Zealand’s Pharmaceutical…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesceftaroline fosamilFinancialJanssen-CilagJohnson & JohnsonNew ZealandPharmaceuticalPricingRemicade

Medivir concludes Swedish agreement on Olysio-based treatment for hepatitis C

Medivir concludes Swedish agreement on Olysio-based treatment for hepatitis C

31-10-2014

Swedish drugmaker Medivir says it has entered into an agreement with Swedish county councils regarding…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalPricingRegulationSweden

NICE recommends Pradaxa for DVT and PE

NICE recommends Pradaxa for DVT and PE

31-10-2014

In draft guidance published today, the UK health costs watchdog the National Institute for Health and…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Under US pressure, Indian government is getting its act together on IP matters

Under US pressure, Indian government is getting its act together on IP matters

27-10-2014

The pressure from the US government on India seems to be working. With India's intellectual property…

IndiaPatentsPharmaceuticalPoliticsPricing

Russian government to introduce state regulation of drug prices in domestic market

Russian government to introduce state regulation of drug prices in domestic market

27-10-2014

The Russian government is considering introducing state regulation of prices for drugs in the country,…

PharmaceuticalPoliticsPricingRussiaRussian government

UK’s NICE backs another use for Bayer’s Xarelto

UK’s NICE backs another use for Bayer’s Xarelto

23-10-2014

In draft guidance published today for consultation, the UK’s health costs watchdog the National Institute…

BayerCardio-vascularPharmaceuticalPricingRegulationUKXarelto

NICE recommends another new skin cancer drug, GSK’s Tafinlar

22-10-2014

The UK National Institute for Health and Care Excellence (NICE) has issued final guidance recommending…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationTafinlarUK

IQWiG finds no added benefit for GSK’s Anoro Ellipta in COPD

21-10-2014

According to the findings of an early benefit assessment under the German Act on the Reform of the Market…

Anoro ElliptaGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationRespiratory and Pulmonary

New report: The myth of high Danish medicine prices

20-10-2014

The price-cap agreements between Lif, the Danish pharmaceutical industry group, and the government help…

DenmarkGenericsPharmaceuticalPricing

NICE reverses guidance on Novartis’ Glivec for GIST

NICE reverses guidance on Novartis’ Glivec for GIST

17-10-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

1 to 25 of 596 results

Back to top